Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

With a market cap of $149.1 billion, Amgen Inc. (AMGN) is renowned for its innovative human therapeutics across oncology, cardiovascular, inflammation, bone health, and nephrology. With a robust ...

On the buying side, ARK’s ARKG ETF acquired 2161 shares of biopharmaceutical giant Amgen Inc (NASDAQ ... This article was generated with the support of AI and reviewed by an editor.

and $2.25 billion psoriasis therapy Otezla (apremilast) also in the final years of patent protection. Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues.

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

If the provided guidance does not resolve your issue, you may have the opportunity to fill out a support form for further assistance. To clarify this process, let’s review the steps to contact ...